Clinical trials: Multiple Myeloma, Newly Diagnosed
Newly Diagnosed Multiple Myeloma
Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation
The investigators will conduct randomized and controlled clinical studies in order to preliminarily explore the efficacy and safety of low-dose cyclophosphamide and lenalidomide in maintenance therapy for MM that is not suitable…
- Trial name
- NCT06324266
- Testing
- Cyclophosphamide, Lenalidomide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jinling Hospital, China
Newly Diagnosed Multiple Myeloma
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have…
- Trial name
- NCT03733691
- Testing
- Ixazomib, Lenalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Oncotherapeutics
Newly Diagnosed Multiple Myeloma
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients.
- Trial name
- NCT03948035
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 56 sites in Austria, Germany
- Volunteers
- 576 people
- Sponsor
- Wuerzburg University Hospital
Newly Diagnosed Multiple Myeloma
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.
- Trial name
- MM (NCT04348006)
- Testing
- Bortezomib 3.5 MG
- Where
- Iraq
- Sponsor
- Al-Rasheed University College
Newly Diagnosed Multiple Myeloma
Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
This is an observational, multi-center, non-interventional study, which is designed to evaluate the safety and efficacy of daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone (D-VTD) Regimens in NDMM…
- Trial name
- NCT05561049
- Testing
- Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed Multiple Myeloma
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
The study is designed as a randomized, controlled, open-label, assessor blind, multicenter superiority trial with three parallel groups, and primary endpoint of immunophenotypic complete responses at 18 months after…
- Trial name
- NCT03742297
- Testing
- Lenalidomide., Carfilzomib, Bortezomib
- Where
- 58 sites in Spain
- Volunteers
- 462 people
- Sponsor
- PETHEMA Foundation
Newly Diagnosed Multiple Myeloma
A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM
This is an open-label, single arm study to access the effect of treatment with D-VRD in patients with newly diagnosed standard risk multiple myeloma.
- Trial name
- NCT05088330
- Testing
- Daratumumab
- Volunteers
- 76 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed, Previously Untreated Multiple Myeloma
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma cells at the time of progression than those…
- Trial name
- NCT01891643
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab
- Where
- 14 sites in United States, Greece and 2 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Exercise
This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further…
- Trial name
- NCT01809717
- Testing
- Weight Lifting Exercises
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Newly Diagnosed Multiple Myeloma
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.
- Trial name
- NCT00405756
- Testing
- Lenalidomide: Double-blind Induction, Melphalan, Prednisone
- Where
- 98 sites in Australia, Austria and 20 more
- Volunteers
- 459 people
- Sponsor
- Celgene Corporation
Newly Diagnosed Myeloma Patient Above 65 Years Old
Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years
Autologous stem cell transplantation remains the gold standard of treatment for newly diagnosed patients under the age of 65. Even though it is also regularly performed above the age of 65, there are very few data in this patient…
- Trial name
- LATMM (NCT01671826)
- Where
- 6 sites in France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Newly Diagnosed, Multiple Myeloma
Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in very elderly patients.
- Trial name
- IFM 01/01 (NCT00644306)
- Testing
- Thalidomide, melphalan, prednisone, melphalan, prednisone, thalidomide
- Where
- France
- Volunteers
- 232 people
- Sponsor
- Central Hospital, Nancy, France
Multiple Myeloma, Newly Diagnosed
Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm characterized by proliferation of neoplastic plasma cells in bone marrow (BM).
- Trial name
- NCT00166855
- Testing
- dynamic MRI and bone marrow sampling
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital